LONDON (Alliance News) - BTG PLC Thursday said it expects its revenue in the financial year that ended on Tuesday to be above the guidance range it had previously provided, and revenue to grow strongly in the year that has just begun.
The healthcare company said it now expects revenue for the year to March 31 to be above the previous guidance it gave of GBP345 million to GBP360 million, including revenue from the PneumRx acquisition that was completed in early January. It then expects revenue to grow strongly in the current financial year to between GBP410 million and GBP440 million on a constant currency basis.
It will book GBP8 million of acquisition-related costs in the financial year that just ended, as well as the GBP8 million of costs it had previously reported related to the settlement of the CroFab litigation, meaning total exceptional costs for the year are expected to be GBP16 million.
By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1
Copyright 2015 Alliance News Limited. All Rights Reserved.
